BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 11239535)

  • 1. Role of periovulatory luteinizing hormone concentrations during assisted reproductive technology cycles stimulated exclusively with recombinant follicle-stimulating hormone.
    Esposito MA; Barnhart KT; Coutifaris C; Patrizio P
    Fertil Steril; 2001 Mar; 75(3):519-24. PubMed ID: 11239535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone.
    Cabrera RA; Stadtmauer L; Mayer JF; Gibbons WE; Oehninger S
    Fertil Steril; 2005 Jan; 83(1):42-8. PubMed ID: 15652885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of LH during ovarian stimulation: analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH.
    Balasch J; Vidal E; Peñarrubia J; Casamitjana R; Carmona F; Creus M; Fábregues F; Vanrell JA
    Hum Reprod; 2001 Aug; 16(8):1636-43. PubMed ID: 11473955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon).
    de Jong D; Macklon NS; Eijkemans MJ; Mannaerts BM; Coelingh Bennink HJ; Fauser BC;
    Fertil Steril; 2001 Apr; 75(4):688-93. PubMed ID: 11287020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction.
    Westergaard LG; Laursen SB; Andersen CY
    Hum Reprod; 2000 May; 15(5):1003-8. PubMed ID: 10783342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose human chorionic gonadotropin may improve in vitro fertilization cycle outcomes in patients with low luteinizing hormone levels after gonadotropin-releasing hormone antagonist administration.
    Propst AM; Hill MJ; Bates GW; Palumbo M; Van Horne AK; Retzloff MG
    Fertil Steril; 2011 Oct; 96(4):898-904. PubMed ID: 21839437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of clomiphene citrate on follicular and luteal phase luteinizing hormone concentrations in in vitro fertilization cycles stimulated with gonadotropins and gonadotropin-releasing hormone antagonist.
    Tavaniotou A; Albano C; Smitz J; Devroey P
    Fertil Steril; 2002 Apr; 77(4):733-7. PubMed ID: 11937125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy.
    Kolibianakis EM; Albano C; Kahn J; Camus M; Tournaye H; Van Steirteghem AC; Devroey P
    Fertil Steril; 2003 Apr; 79(4):873-80. PubMed ID: 12749423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists.
    Frydman R; Howles CM; Truong F
    Hum Reprod; 2000 Mar; 15(3):520-5. PubMed ID: 10686190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal stimulation IVF using clomiphene citrate and oral contraceptive pill pretreatment for LH suppression.
    Branigan EF; Estes MA
    Fertil Steril; 2000 Mar; 73(3):587-90. PubMed ID: 10689017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LH serum levels during ovarian stimulation as predictors of ovarian response and assisted reproduction outcome in down-regulated women stimulated with recombinant FSH.
    Peñarrubia J; Fábregues F; Creus M; Manau D; Casamitjana R; Guimerá M; Carmona F; Vanrell JA; Balasch J
    Hum Reprod; 2003 Dec; 18(12):2689-97. PubMed ID: 14645193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian stimulation with human and recombinant gonadotropin - comparison of in vitro fertilization efficiency with use of time-lapse monitoring.
    Wdowiak A; Bojar I
    Reprod Health; 2015 Dec; 12():113. PubMed ID: 26667662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.
    Berkkanoglu M; Isikoglu M; Aydin D; Ozgur K
    Fertil Steril; 2007 Sep; 88(3):665-9. PubMed ID: 17292895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of recombinant human luteinizing hormone for ovulation stimulation in in vitro fertilization-embryo transfer].
    Xu SR; Li Y; Liu H; Li HY; Tang R; Gao Q; Sheng Y; Chen ZJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Jun; 45(6):420-3. PubMed ID: 21029591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IVF/ICSI outcome and serum LH concentration on day 1 of ovarian stimulation with recombinant FSH under pituitary suppression.
    Bjercke S; Fedorcsak P; Abyholm T; Storeng R; Ertzeid G; Oldereid N; Omland A; Tanbo T
    Hum Reprod; 2005 Sep; 20(9):2441-7. PubMed ID: 15919773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A relative reduction in mid-follicular LH concentrations during GnRH agonist IVF/ICSI cycles leads to lower live birth rates.
    Lahoud R; Al-Jefout M; Tyler J; Ryan J; Driscoll G
    Hum Reprod; 2006 Oct; 21(10):2645-9. PubMed ID: 16785261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HCG administration after endogenous LH rise negatively influences pregnancy rate in modified natural cycle for frozen-thawed euploid blastocyst transfer: a pilot study.
    Litwicka K; Mencacci C; Arrivi C; Varricchio MT; Caragia A; Minasi MG; Greco E
    J Assist Reprod Genet; 2018 Mar; 35(3):449-455. PubMed ID: 29147846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.